Kathy McGroddy-Goetz is the Head of Strategic Partnerships at Medidata Solutions. She is responsible for managing strategic collaborations with key industry leaders to transform clinical trials for patients, sites and sponsors.
Dr. McGroddy-Goetz joined Medidata after a 26 year career at IBM innovating at the intersection of advanced technologies and new business models, with an emphasis on Healthcare and Life Sciences solutions. She spent two years as Director of Corporate Technology, leading IBM’s technology strategy, and has significant expertise in developing innovative medical imaging solutions. She played a critical role in the corporation’s launch of Watson Health, called a “moon shot” by CRO Ginni Rometty and led the Global Strategic Partnerships & Alliances team for Watson Health for three years.
Dr. McGroddy-Goetz earned a BS in physics from SUNY Binghamton and a PhD in molecular biophysics from Cornell University, where she studied protein-ligand interactions using NMR spectroscopy and molecular dynamics simulations. She holds five patents and is a frequent speaker at industry and technology conferences.
Healthcare Consumerism & Preventive Care
Gracelyn McDermott, M.B.A.
Executive Director at Kaiser Permanente
Santosh Venkatesha, M.B.A.
CEO of Vigilant Medical, Inc.
Santosh Venkatesha is the Founder & CEO of Vigilant Medical which is a Healthcare IT company developing smart medical imaging solutions. The first commercial product, ImageShare, focused on enhancing physician collaboration and decision making with a HIPAA compliant web-based application currently used by medical centers across the US and worldwide. Over 30,000 patients benefit from this technology each year. Recently, his focus has turned to use of machine learning techniques to improve cardiac image analysis and to aid physician interpretation. This work has been begun in collaboration with Duke University in 2018 as part of a successfully awarded NIH SBIR Phase 1 grant.
Prior to Vigilant Medical, Santosh was part of the management team of Infinite Biomedical Technologies from 1999 to 2009. He grew the company with the Johns Hopkins co-founders from startup to early stage starting from $300k to over $20M in funding. This company focused on translational research and development of medical diagnostics and devices in the application areas of cardiology, neurology, OB/GYN, GI, and upper limb amputees. This led to regulatory 510k approval for multiple products and eventual commercialization that continues today.
Santosh has a BSE in Biomedical Engineering from Duke University and a MBA from the Wharton Business School of the University of Pennsylvania.
Hassan A. Tetteh, MD, MPA, MBA, FACS
Chief Medical Informatics Officer of the US Navy
Dr. Hassan Tetteh is a U.S. Navy Captain and Associate Professor of Surgery at the Uniformed Services University of the Health Sciences and adjunct faculty at Howard University School of Medicine. Currently, Tetteh is a staff Thoracic Surgeon for MedStar Health and Walter Reed National Military Medical Center. He leads a Specialized Thoracic Adapted Recovery (STAR) Team, in Washington, D.C., and his research in thoracic transplantation aims to expand heart and lung recovery and save lives. Tetteh is board certified in thoracic surgery, general surgery, clinical informatics, and healthcare management, and is a Fellow of the American College of Surgeons and American College of Healthcare Executives
Caroline Popper, M.D.
Co-Founder & President of Popper and Co.
Dr. Caroline Popper founded Popper and Company with Ken Walz more than ten years ago to address inefficiencies in health care by helping life science companies develop and commercialize new technology. Dr. Popper has more than 20 years of hands-on operating experience within health care companies and has a background as a physician (University of the Witwatersrand, South Africa) and an internist and pathologist (Johns Hopkins University, Baltimore).
Dr. Popper has managed a wide spectrum of diagnostics, device and drug discovery businesses in both Fortune 500 and start-up settings, at amongst others, Becton Dickinson, bioMerieux, and MDS. Now, at Popper and Co., she combines those experiences with her clinical experience to help clients interpret relevant market forces, develop strategies and create partnerships to thrive in the global changing health care landscape.
VP & President-Elect of the Maryland HIMSS Chapter; Founder & CEO of STS Consulting Group, LLC.
Pothik Chatterjee, M.B.A.
Executive Director of Innovation at LifeBridge Health
Companion Diagnostics & Biomarkers
Justin Sacks, M.D.
Associate Professor of Plastic & Reconstructive Surgery and Director of Oncological Reconstruction at The Johns Hopkins University School of Medicine
Dr. Justin Sacks is an associate professor of plastic and reconstructive surgery at the Johns Hopkins University School of Medicine. Dr. Sacks is an expert in head-to-toe reconstructive surgery of the body, including the head and neck, breast, chest, abdomen, pelvis and extremities. Among his specialties is reconstructive surgery following post-traumatic injury and oncologic surgery.
Dr. Sacks earned his M.D. from Mount Sinai School of Medicine and completed his residencies in plastic surgery and general surgery at Mount Sinai Medical Center. He performed fellowships in microsurgery at the University of Texas MD Anderson Cancer Center and in plastic surgery at the University of Pittsburgh Medical Center. Dr. Sacks comes to Johns Hopkins from a faculty appointment at the University of Texas MD Anderson Cancer Center.
His research interests involve modalities to induce donor-specific tolerance in composite tissue allograft constructs, such as the face and hand.
Dr. Sacks is certified in plastic surgery by the American Board of Surgery. He is an associate fellow member of the American College of Surgeons and a member of the American Society of Plastic Surgeons, American Society of Reconstructive Microsurgery and Plastic Surgery Research Council. Dr. Sacks is a founding member of the American Society of Reconstructive Transplantation.
Dr. Sacks was recently selected as a 125 Living the Hopkins Mission Honoree.
Edward Bessman, M.D., M.B.A.
Senior Director of Faculty Practice at The Johns Hopkins University School of Medicine
A native of Boston, MA, Dr. Edward Bessman has been affiliated with The Johns Hopkins University since the age of 5. He received his undergraduate degree from Hopkins in 1977 and his medical degree from Harvard University and the Massachusetts Institute of Technology in 1981. After residency training in emergency medicine at the University of Maryland Medical System in 1985 he went into the community to practice emergency medicine as well as taking on a part-time faculty position with the Georgetown University Department of Emergency Medicine. He subsequently joined the emergency medicine faculty at the Johns Hopkins School of Medicine in 1992 with his clinical appointment at what was then the Francis Scott Key Medical Center, now Johns Hopkins Bayview Medical Center (JHBMC). He became Chairman of the Department of Emergency Medicine at JHBMC in 1997, and received his MBA in Medical Services Management from the Johns Hopkins Carey Business School in 2011.
Dr. Bessman’s interests include operations improvement, service excellence, and behavioral economics. He has scholarly publications regarding all phases of Emergency Department (ED) throughput, including triage, diagnosis, consultation, care management, admission and discharge. Under his guidance several innovative programs have been developed at JHBMC including a multidisciplinary combined inpatient/outpatient ED Observation Unit (1994), a credentialing pathway for ED point-of-care ultrasound (1999), a post-graduate residency in emergency medicine for Physician Assistants (2003) and a re-design of the admissions process with the Department of Medicine that has promoted throughput and patient safety and has been copied by many other institutions (2008).
In his role as Chairman he fostered an environment of innovation and collaboration that has made the JHBMC ED a preferred site for clinical investigation as well as for educational opportunities for learners from a variety of disciplines. In July of 2017, after leading the transition to new clinical space, Dr. Bessman stepped down as Chairman to take on a role as Senior Director of Faculty Practice across the academic division.
Dr. Bessman also performs Urban Search and Rescue operations with the Federal Emergency Management Agency as a member of Maryland Task Force-1. He is certified as a Confined Space Medical Specialist and as a Lead Instructor for the Confined Space Medical Specialist training curriculum. Notable deployments include the Oklahoma City bombing (1995), the attack on the Pentagon (2001) and Superstorm Sandy (2012). In his free time Dr. Bessman enjoys any outdoor activity on a board, training for triathlons, travel and experimenting with barbecue, smoking and sous-vide.
Dan Edelstein, M.B.A.
Director of Commercial Operations at Sysmex Inostics
Drug Development & Targeted Therapies
Aiman Shalabi, PharmD
Vice President R&D, Cell and Gene Therapies (NYESO)
Seasoned Biotech Executive
Former CEO of Altimmune (Most Recent)
Former Executive Director at GenVec
Boro Dropulić, Ph.D., M.B.A.
Chief Science Officer and General Manager at Lentigen Technology Inc., A Miltenyi Biotec Company
Dr. Boro Dropulic, Ph.D., M.B.A is currently the Chief Science Officer and General Manager at Lentigen Technology Inc. He founded Lentigen Corporation in December 2004 and served as its Chief Scientific Officer and President until July 2014. Dr. Dropulic is one of the leading experts in lentiviral vector technology. Previously, he was the Founder and Chief Scientific Officer at VIRxSYS Corporation, where he successfully led a multidisciplinary team to initiate and complete the first ever lentiviral vector clinical trial in humans. Prior to that, Dr. Dropulic was an Instructor and Adjunct Assistant Professor at The Johns Hopkins University School of Medicine, where he was the first to develop an HIV-based vector targeted to inhibit the replication of the HIV/AIDS virus. He served as a Director of Lentigen Corporation. He is a Member of Scientific Advisory Board of Greenwich Biotech Partners. Dr. Dropulic is a Member of the Infectious Diseases and Industrial Liaisons Committees for the American Society of Gene Therapy and a member of the Editorial Board of the journal Human Gene Therapy. He was a Fogarty Fellow at the National Institutes of Health, where he worked on developing transgenic animals using embryonic stem cell technology, understanding molecular aspects of HIV replication and gene therapy for HIV/AIDS. Dr. Dropulic obtained his Ph.D. from the University of Western Australia, focusing upon how viruses cause disease in the body. He also holds an M.B.A. from The Johns Hopkins University and a B.Sc., with honors, from the University of Western Australia.
Daniel J. Durand, M.D.
Chief Innovation Officer at LifeBridge Health
Dr. Daniel J Durand, MD (“Dan”) is a physician executive with deep expertise in healthcare innovation, biomedical research, and value-based care.
Dr. Durand leads Innovation and Research for LifeBridge Health, a health system serving over 1 million patients with $2.5 B in revenue. Dan is accountable for overseeing all of LifeBridge’s projects, investments, and partnerships related to biomedical research, digital health, and value-based contracting. He also continues to practice medicine as the Chairman of Radiology for all four Lifebridge Health hospitals.
Over the course of his career, Dan has studied and served at the world’s leading medical organizations, including public, private, and academic institutions. His credibility as an executive is built upon a foundation of diverse but rigorous experiences in the sciences, clinical practice, general management, and entrepreneurship.
Dan’s writing has appeared in top journals such as The New England Journal of Medicine (NEJM) and the Journal of the American Medical Association (JAMA). He regularly lectures at national conferences on topics related to medical innovation.